Nature Reviews Drug Discovery

Article	Citations
The importance of persistence in cancer drug development	2147
A new path to targeted protein degradation?	1266
A specific biomarker for insoluble tau	834
Targeting tumour-associated bacteria	714
The improving benefit–risk balance of phase I cancer trials	664
Neutralizing Zika virus	553
Vaccine exposes tumours to immune cell attack	534
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	532
Promoting tissue repair after heart attack	488
mRNA-encoded monoclonal antibody fights CHIKV	472
AI serves up target and inhibitor for lung fibrosis	464
Hypoimmune iPSCs escape immune detection	435
Glucose-sensitive insulin protects against hypoglycaemia	424
Tumour cells get a dendritic cell makeover	402
Degrading cell-free DNA to prevent recurrent stroke	393
FDA new drug approvals in Q1 2023	392
Apolipoprotein L2 inhibitor mitigates fibrosis	388
Lipid nanoparticle ferries therapeutic mRNA to the placenta	366
FDA approves second TTR stabilizer for cardiac amyloidosis	332
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	324
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	300
Top companies and drugs by sales in 2021	292
Targeting drug-resistant glioblastoma	288
Evolution of innovative drug R&D in China	270
FDA approves a c-MET-targeted ADC for lung cancer	268

2022 FDA approvals	267
Anti-tau antibody stumbles in phase II Alzheimer trial	266
mRNA vaccines for infectious diseases — advances, challenges and opportunities	265
Chemical engineering of CRISPR–Cas systems for therapeutic application	257
Small-molecule discovery through DNA-encoded libraries	249
Targeting the Hippo pathway in cancer	241
New antibiotic for urinary tract infections nabs FDA approval	239
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	228
Increasing the potency of T cell therapies	223
Pushing both sides of the drug pricing aisle	218
Reflections on 10 years of the FDA’s breakthrough therapy designation	211
Blocking breast cancer metastasis	206
Rewired proteostasis in KRAS inhibitor resistance	190
Small molecule improves muscle function in myasthenia gravis	183
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	182
R&D re-balancing act	182
Host-directed antiviral blocks SARS-CoV-2 entry	172
The significance of blockbusters in the pharmaceutical industry	167
Amylin takes another shot at the obesity prize	165
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	161
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	160
Inhibiting ASGR1 boosts cholesterol removal	159
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	158
FDA new drug approvals in Q2 2023	155
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	151
TCR-engineered T cells get personal	147
FDA approves second BCMA-targeted CAR-T cell therapy	144
Mimicking the health benefits of exercise	134
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	134
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	130
Base editors hit the clinic	130
The antibody–drug conjugate landscape	128
Screening ultra-large virtual libraries	128
Combating antimicrobial resistance in malaria, HIV and tuberculosis	120
Pan-coronavirus vaccine pipeline takes form	118
A call to action for translational sciences in COVID-19 and future pandemics	115
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	107
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	104
The emerging role of mass spectrometry-based proteomics in drug discovery	103
Antibody–drug conjugates come of age in oncology	101
Phenotypic drug discovery: recent successes, lessons learned and new directions	99
Gut metabolite mediates nerve repair	98
Reducing IL-2 toxicity	96
Agonist antibody lowers blood pressure	94
A novel single-agent antibiotic	94
Immunology on the brain	92
Multi-TACs target solid tumours	91
The malignant melanoma market	90
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	87
Neglected tropical diseases go global	84

Monkeypox mRNA vaccine protects mice and macaques	81
The European Innovation Network as a hub for medicines innovation in Europe	81
Anti-IL-11 antibody shows anti-ageing properties	80
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	80
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	78
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	77
Author Correction: PI3K inhibitors are finally coming of age	76
What does AlphaFold mean for drug discovery?	75
Ribosome inhibitor combats bacterial drug resistance	73
Frameworks for transformational breakthroughs in RNA-based medicines	73
LRRK2-targeted Parkinson disease drug advances into phase III	70
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	69
Engineering a compact genome-editing tool	68
Avidity in antibody effector functions and biotherapeutic drug design	68
Engineered parasite delivers proteins to the brain	68
Upcoming market catalysts in Q4 2023	67
Covalent inhibitor engages oncogenic AKT kinase	67
Delivering genome editing tools to primary cells	67
RNA structure guides antiviral ASO design	67
Publisher Correction: Roflumilast	65
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	62
A rush of CRISPR to the lungs	62
Trends in the development of cellular and gene therapy in China	59
Broader horizons for cereblon glue degraders	59
The non-small-cell lung cancer drug market	59
Accelerating precision oncology by converging pragmatic trials and real-world evidence	57
Targeting protein disorder: the next hurdle in drug discovery	57
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	52
MYC in cancer: from undruggable target to clinical trials	52
Investigating the origins of recent pharmaceutical innovation	51
FDA approves first PSMA-targeted radiopharmaceutical	51
Promoting efferocytosis heals diabetic wounds	48
AAV-based in vivo gene therapy for neurological disorders	47
V-ATPase inhibitor targets Ras-mutant cancers	44
Identification of neoantigens for individualized therapeutic cancer vaccines	44
A bacteria-derived oral tumour vaccine	43
RNA delivery heats up cold tumours	43
Three-step cures for autoimmune diseases?	43
Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases	41
Microbial ‘dark matter’ yields new antibiotic	40
Designing novel macrocyclic drugs	40
Upcoming market catalysts in Q4 2024	39
Can large, simple trials bring drug developers back to common diseases?	38
A new drug target for NRAS(Q61) mutant-expressing cancers	37
2023 FDA approvals: unprecedented volume at moderate value	36
Glue-based KRAS inhibitors make their debut cancer trial mark	36
The market for ulcerative colitis	35
Understanding LAG3 immune checkpoint function	35
Hinge modifier approach opens door to drugging HECT E3 ligases	35
Analysis of China-to-West pharmaceutical licensing deals in 2024	33
FDA approves cell-sheet-based gene therapy for severe skin disease	33
Cartilage regeneration for osteoarthritis	32
The case for cell-penetrating peptides	31
Novel strategies to manage CAR-T cell toxicity	31
PPAR agonists provide new treatment options for inflammatory liver disease	30
Neurotensin receptor modulator safely tackles pain	30
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	30
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	29
RNA chemistry and therapeutics	29
Therapeutically harnessing extracellular vesicles	29
De novo design of macrocycles	29
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	28
Synthetic cytokine circuit targets solid tumours	28
miR-21 antagomir reverses COPD pathology	27
Refining HIV pre-exposure prophylactic agents	27
Targeting sigma receptor 1 in long QT syndrome	26
Transcription reprogramming to enhance CAR-T cell function	25
Designing closure-stabilizing integrin inhibitors	25
Designing a novel synthetic receptor	24
A step closer to in vivo editing of haematopoietic stem cells	24
Publisher Correction: Evolution of the market for mRNA technology	24
Novel schizophrenia therapy filed for FDA approval	24
A faster route to antidepressant activity	24
FDA approves 21-valent pneumococcal vaccine	23
PD1 × VEGF blocking bispecifics for cancer draw big backing	23
In vivo CAR T cells move into clinical trials	23
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	22
Improving efficacy of ASO therapy in SMA	22
FDA approves decades-old maribavir for CMV infection	22
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	21

Top product forecasts for 2025	20
FDA approves PI3Kα inhibitor that does double duty as a degrader	20
Enhancing CAR-T cell efficacy through IFN ablation	19
Unmet needs in vaccine development	19
FDA approves first factor XIIa inhibitor, for hereditary angioedema	19
Genome-editing medicinal products: the EMA perspective	19
CAR T cells take to the airways	19
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	18
Targeting galectin-driven regulatory circuits in cancer and fibrosis	18
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	18
Sequential immunotherapy: towards cures for autoimmunity	18
Anti-histamines boost immunotherapy	18
RNAi-based drug design: considerations and future directions	18
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	18
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	17
Bacteria tag tumours for CAR-T cell attack	17
Drugging the efferocytosis process: concepts and opportunities	17
Understanding the effects of antibiotic combinations	17
Acyl-lysine reader inhibitor blocks AML progression	16
Synthesizing portimines	16
Brain glucose mediates amphotericin B tolerance	15
Treating cannabis use disorder	15
Stalled molecular motor inhibits tumour growth	15
Rediscovering hygromycin A for Lyme disease treatment	15
In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics	15
Open-science drug discovery for COVID-19	15
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	15
Putting a PIN in pancreatic cancer	15
Trustworthy AI for safe medicines	14
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	14
Epigenetic editor silences prion protein	14
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	14
Neurons give metastatic cells a push	14
ASO targets DNA repair protein to combat Huntington disease	14
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	14
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	13
The KRAS crowd targets its next cancer mutations	13
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	13
Advanced technologies for the development of infectious disease vaccines	13
Insights into new approach methodology innovation: an EMA perspective	13
opnMe.com: a digital initiative for sharing tools with the biomedical research community	13
Building on the momentum of N-of-1 base editor therapies for rare diseases	13
mRNA flu shots move into trials	13
Thinking outside the box: non-canonical targets in multiple sclerosis	13
Bispecific antibodies in oncology	13
Trends in the drug target landscape for autoimmune diseases	13
Upcoming market catalysts in Q3 2023	12
Alnylam scores big pharma support for angiotensinogen silencer	12
Understanding sphingosine-1-phosphate transport	12
A new antibiotic for A. baumannii	12
Antibody cocktail eliminates ebolaviruses	12
A type 1 regulatory T cell-based therapy	12
FDA approves first two drugs for rare Niemann–Pick disease	11
Nonhormonal target for endometriosis	11
Gene editing addresses antithrombin deficiency	11
Top product forecasts for 2022	11
FDA releases tissue-agnostic cancer drug draft guidance	11
Setting GPCRs free	11
The renal cell carcinoma drug market	11
Understanding immunomodulatory antibody agonism	11
FDA approves first chikungunya vaccine	10
DUBTACs for targeted protein stabilization	10
Membrane transporters in drug development and as determinants of precision medicine	10
Hooking FSH as a potential target for Alzheimer disease	10
Targeting cytokine networks in neuroinflammatory diseases	10
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	10
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	10
Ramping up mitochondrial DNA replication	10
Targeting ALDH1B1 in colorectal cancer	9
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	9
Inhibiting metallo-β-lactamases	9
Two-pronged approach for macular degeneration	9
Phosphatase inhibitor drives anticancer immune responses	9
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	9
Chromatin-targeted drug discovery at “a very special moment”	9
Targeting expanded trinucleotide repeats	9
FDA approves first claudin-18.2-targeted antibody for gastric cancer	9
Macrophages as tools and targets in cancer therapy	9
mRNA vaccine for Lyme disease prevention	9
FDA approves second anti-amyloid antibody for Alzheimer disease	8
New route to target RAS	8
Targeting ephrin signalling in sepsis	8
Antibody drug conjugate combats inflammation	8
Novel drug targets in 2021	8
Mapping cysteine ligandability	8
BacPROTAC to treat tuberculosis	8
FDA approves PI3K inhibitor for a rare immune disorder	7
Anti-tau antibody failures stack up	7
Developing an IKZF2 glue degrader	7
Opportunities for mitochondrial disease gene therapy	7
ALS antisense drug falters in phase III	7
Advances in the treatment of systemic lupus erythematosus	7
Scooping up all the drugs	7
Understanding semaglutide action in the brain	7
RNF41 reverses liver fibrosis	7